INS and type 2 diabetes mellitus: In this large, pooled analysis of prospective, randomized, controlled clinical trials in patients with type 2 diabetes, more than half of the patients previously uncontrolled on 0, 1 or 2 OADs with baseline HbA1c of 8.7–9.1% achieved a target HbA1c ≤7.0% after 24 weeks of treatment with the addition of basal insulin, while continuing the oral agent(s).